貝瑞基因(000710.SZ)：福建和瑞B輪股東君聯景明擬追加對B輪投資額5000萬元
格隆匯10月18日丨貝瑞基因(000710.SZ)公佈，公司參股子公司福建和瑞基因科技有限公司(“福建和瑞”)B輪投資人於近日完成對福建和瑞6.42億元投資，該投資對應福建和瑞1196.1757萬元新增註冊資本及投資完成後福建和瑞13.83%股權，公司與相關方籤訂了《有關福建和瑞基因科技有限公司之股東協議(第三次修訂)》(具體內容詳見公司披露的《關於放棄子公司增資擴股優先認繳權暨關聯交易的公吿》(公吿編號：2021-045)(“B輪第一次投資”)。
福建和瑞B輪股東珠海君聯景明股權投資企業(有限合夥)(“君聯景明”)擬追加對福建和瑞B輪投資額5000萬元，此次追加投資完成後，君聯景明將合計以1.5億元認購福建和瑞279.4803萬元新增註冊資本，B輪投資人將合計以6.92億元認購福建和瑞1289.3358萬元新增註冊資本，公司與相關方將簽訂《有關福建和瑞基因科技有限公司之股東協議(第四次修訂)》。此次交易完成後，福建和瑞股權結構如下：
腫瘤早篩早診具有廣闊的市場發展前景及應用需求，但前期需要大量的研發資金投入和較長的研發週期，後期需要持續的市場推廣及產品渠道投入以完成商業化落地。此次交易系福建和瑞B輪第一次投資的延續，將進一步為福建和瑞布局腫瘤早篩早診市場提供資金保障。
福建和瑞肝癌早篩產品“萊思寧”的推出實現了公司通過參股子公司形式在腫瘤學領域由晚期檢測向早期篩查的戰略佈局，若未來“萊思寧”完成商業轉化及產品化，將進一步豐富公司基因檢測產業鏈版圖，提高公司市場地位。同時，此次交易系參考福建和瑞B輪第一次投資條款做出，公司未對福建和瑞投資人承諾業績或保底收益，公司繼續擁有未來購買福建和瑞其他股東股權的選擇權。因此，公司將在風險可控的條件下享受福建和瑞未來發展的收益，不存在損害公司及全體股東利益的情形。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app！
Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.
